Literature DB >> 16485887

Infliximab associated new-onset psoriasis.

David R Adams1, Tamy Buckel, Jennifer A Sceppa.   

Abstract

Infliximab infusion is not yet FDA-approved for psoriasis but has been reported to be very effective for plaque psoriasis. We report 2 patients without a history of psoriasis who after administration of infliximab for their inflammatory bowel disease experienced new onset, biopsy confirmed psoriasis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16485887

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN： 1545-9616            Impact factor:   2.114


  4 in total

Review 1.  Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Authors:  Isabelle Cleynen; Séverine Vermeire
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-03       Impact factor: 46.802

2.  Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.

Authors:  Maria Sole Chimenti; Marina Talamonti; Lucia Novelli; Miriam Teoli; Marco Galluzzo; Paola Triggianese; Roberto Perricone
Journal:  J Dermatol Case Rep       Date:  2015-09-30

3.  The changing face of spondyloarthropathies under TNF α blockade.

Authors:  Ori Elkayam; Irena Litinsky; David Levartovsky; Dan Caspi
Journal:  Open Rheumatol J       Date:  2008-11-14

4.  Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.

Authors:  Rotraut Mössner; Diamant Thaci; Johannes Mohr; Sylvie Pätzold; Hans Peter Bertsch; Ullrich Krüger; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2008-02-01       Impact factor: 3.017
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.